TECH EV/EBITDA Analysis

Bio-Techne's EV/EBITDA of 30.8x means that the company's total enterprise value (market cap plus debt minus cash) is 30.8 times its earnings before interest, taxes, depreciation, and amortization — a high multiple that indicates investors are paying a premium for each dollar of operating profit.

This sits well above the healthcare sector median of 14.8x, placing the stock in the 89th percentile of its peer group, meaning roughly 89% of competitors have a lower valuation multiple. The metric has been increasing over the last eight quarters; year-over-year it rose 27.0%, though the quarter-over-quarter change was nearly flat at -0.1%. The combination of a very high current valuation with a sustained upward trend signals that the stock carries elevated valuation risk — further price appreciation depends on maintaining or accelerating growth expectations that are already priced in. This supports the overall NEUTRAL verdict, because the expensive multiple offers limited margin of safety, while the nearly flat quarterly change suggests the upward momentum may be stalling.

Frequently Asked Questions

Closest Sector Peers